The most severe patients with high cholesterol disease will now have easier access to newer, effective therapies. Medicines based on PCSK9 inhibition or inhibition of PCSK9 synthesis have been included in social security as of 1 January!
As of 1 January 2024, there are legislative changes to support the treatment of patients with FH, including 2 new EC100 priority points (see below). The 2 new EC100 points now allow outpatient specialist outpatient clinics and inpatient medical centres to prescribe newer, effective cholesterol-targeting medicines with 100% reimbursement for internal medicine and cardiology.
Since its inception, the FH group of SZIVSN has been fighting for the widest possible availability of new, effective cholesterol-lowering therapeutic options. Back in 2016, we wrote our first official letter of support for newer drugs, which was followed by many more letters and face-to-face meetings. A few years ago, a major step forward was made, with the individual equity basis for the most needy patients being able to start receiving treatment, but only for a narrow group of patients, with a heavy administrative burden. We are delighted with the changes in the legislation, now published in January, which finally bring the new medicines into formal social insurance.
With the help and supervision of their specialist doctors, Hungarian patients can now receive effective treatments with a significantly reduced documentation burden by paying only the 300Ft box fee.
This change is a cause for celebration ??
This is a huge help for the FH patient community! ??
It means lives, years and more for us FH patients! ???
One of the EC100% points (81) is for the most severe homozygous FH patients, while the second (82) is for secondary prevention in patients with high cholesterol who have a history of heart attack, unstable angina, bypass surgery, stent implantation, stroke, limb vascular surgery or amputation. It is also conditional on the failure of conventional therapies to achieve the required cholesterol targets or on the patient’s intolerance to conventional medicines.